Journal article

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

S-J Dawson, N Makretsov, FM Blows, KE Driver, E Provenzano, J Le Quesne, L Baglietto, G Severi, GG Giles, CA McLean, G Callagy, AR Green, I Ellis, K Gelmon, G Turashvili, S Leung, S Aparicio, D Huntsman, C Caldas, P Pharoah



BACKGROUND: Breast cancer is heterogeneous and the existing prognostic classifiers are limited in accuracy, leading to unnecessary treatment of numerous women. B-cell lymphoma 2 (BCL2), an antiapoptotic protein, has been proposed as a prognostic marker, but this effect is considered to relate to oestrogen receptor (ER) status. This study aimed to test the clinical validity of BCL2 as an independent prognostic marker. METHODS: Five studies of 11 212 women with early-stage breast cancer were analysed. Individual patient data included tumour size, grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human epidermal growth factor recep..

View full abstract


Awarded by Australian NHMRC

Awarded by Cancer Research UK

Awarded by The Francis Crick Institute

Funding Acknowledgements

This work was supported by PhD fellowship grants to SJD from the Commonwealth Scholarship and Fellowship Program and Cancer Research UK. NM was supported by a UICC-ACSBI fellowship for beginning investigators and a travelling fellowship from the Government of Newfoundland, Canada. SEARCH is funded by a programme grant from Cancer Research UK. The immunohistochemical analysis of breast cancers from the MCCS was supported by Australian NHMRC Grants 209057, 251553 and 504711 and by infrastructure provided by The Cancer Council Victoria. We acknowledge the contribution of other MCCS investigators (Professor John L Hopper, Professor Dallas R English, Associate Professor Melissa C Southey and Dr Helen Kelsall). We thank Dr David Tuveson for insightful comments and critical reading of the paper. We also acknowledge the contribution of the Histopathology Core Facility at the CRUK Cambridge Research Institute for the immunohistochemistry performed on the SEARCH and BCCA series.